Literature DB >> 16717227

Diagnostic evaluation of clinically normal subjects with chronic hyperCKemia.

C Fernandez1, A Maues de Paula, D Figarella-Branger, M Krahn, R Giorgi, B Chabrol, M-F Monfort, J Pouget, J-F Pellissier.   

Abstract

The authors analyzed muscle biopsy specimens of 104 patients with creatine kinase activity greater than 500 UI/L (normal 10 to 170 UI/L) without signs of muscle weakness. They achieved a definite or probable diagnosis in 55% of cases. The most frequently identified diseases were glycogen storage diseases, muscular dystrophies, and inflammatory myopathies. The probability of making a diagnosis was higher in children and when creatine kinase level was greater than 2,000 UI/L.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16717227     DOI: 10.1212/01.wnl.0000216144.69630.6e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Hyponatraemia induced hyperCKaemia.

Authors:  Ketki Khandhadiya; Krishnananda Prabhu; K N Shivashankara; Pragna Rao
Journal:  BMJ Case Rep       Date:  2013-09-12

2.  Frequency of the FKRP mutation c.826C>A in isolated hyperCKemia and in limb girdle muscular dystrophy type 2 in German patients.

Authors:  Frank Hanisch; Dörte Grimm; Stephan Zierz; Marcus Deschauer
Journal:  J Neurol       Date:  2009-10-10       Impact factor: 4.849

3.  Asymptomatic hyperCKemia during a two-year monitoring period: A case report and literature overview.

Authors:  Spyridon Klinis; Athanasios Symeonidis; Dimitrios Karanasios; Emmanouil K Symvoulakis
Journal:  Biomed Rep       Date:  2016-11-30

Review 4.  Approach to asymptomatic creatine kinase elevation.

Authors:  Siamak Moghadam-Kia; Chester V Oddis; Rohit Aggarwal
Journal:  Cleve Clin J Med       Date:  2016-01       Impact factor: 2.321

5.  Creatine kinase is associated with reduced inflammation in a general population: The Tromsø study.

Authors:  Svein Ivar Bekkelund; Stein Harald Johnsen
Journal:  PLoS One       Date:  2018-05-29       Impact factor: 3.240

6.  Milder forms of muscular dystrophy associated with POMGNT2 mutations.

Authors:  Yukari Endo; Mingrui Dong; Satoru Noguchi; Megumu Ogawa; Yukiko K Hayashi; Satoshi Kuru; Kenji Sugiyama; Shigehiro Nagai; Shiro Ozasa; Ikuya Nonaka; Ichizo Nishino
Journal:  Neurol Genet       Date:  2015-12-10

7.  Evaluation prevalence of Pompe disease in Iranian patients with myopathies of unknown etiology.

Authors:  Khadijeh Haji Naghi Tehrani; Elmira Sakhaeyan; Elnaz Sakhaeyan
Journal:  Electron Physician       Date:  2017-07-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.